Scholar Rock Holding Corp SRRK
We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (“SMA”) and additional rare, severe and debilitating neuromuscular diseases. 10-K, Item 1
- Headquarters
- Cambridge, MA
- CEO
- David Hallal
- Next results
- around Jan 11, 2027
What changed
36 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Mar 3, 2026 against Feb 27, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 8 checks found nothing to note
-
Auditor change8-K item 4.01 (change in certifying accountant) filed May 12, 2025
-
Cash from operations −$300.0M vs net income −$377.9M (FY ending Dec 31, 2025)
7 more checks with nothing to note
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: External Prepaid and Accrued Research and Development Expenses
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
36 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Unfavorable pricing and reimbursement decisions in the EU could significantly delay or limit patient access to apitegromab, if approved, and materially reduce our anticipated revenues. Even if we obtain marketing authorization, the EU health technology assessment bodies and national payors may impose price reductions, require additional…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
In September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility. This facility was issued a Form 483 by the FDA in July 2025 and the inspection classification of this facility is OAI. The observations were related to the facility and were not specific to…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Patients in ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies, and OPAL, our Phase 2 clinical trial of apitegromab in children under the age of two living with SMA, are receiving apitegromab in conjunction with an approved SMN targeted treatment. These patients are reliant on the continued use and…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
For example, in September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility. This facility was issued a Form 483 by the FDA in July 2025 and the inspection classification of this facility is OAI. The observations were related to the facility and were not…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2020 | FY2021 | FY2022 | FY2025 |
|---|---|---|---|---|
| Revenue | $15.4M | $18.8M | $33.2M | $0 |
| Net income | −$86.5M | −$131.8M | −$134.5M | −$377.9M |
| Operating cash flow | −$60.3M | −$126.8M | −$132.7M | −$300.0M |
| Free cash flow | −$64.4M | −$132.0M | −$133.8M | −$300.6M |
Revenue, FY2018 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$0 ▼ 100.0% in FY2025−$377.9M in FY2025−$300.6M in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
8-KNov 10, 2026Material agreement signed, Quarterly results, Regulation FD disclosure 8-K items 1.01, 2.02, 7.01
-
10-QNov 10, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
BuyOct 27, 2026AKKARAJU SRINIVAS (Director) bought $12.0M open-market purchase on Oct 23, 2026
About the company
Scholar Rock Holding Corp, Cambridge, MA · from the 10-K filed Mar 3, 2026
We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (“SMA”) and additional rare, severe and debilitating neuromuscular diseases. As a leader in the biology of the transforming growth factor beta (“TGFβ”) superfamily, our novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Based on our innovative, proprietary, and scalable technology platform, we are building a world-leading anti-myostatin pipeline.
- Headquarters
- Cambridge, MA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 10, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Mar 3, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SRRK/export.csv") into a cell.